These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30659026)

  • 21. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Vitale SR; Groenendijk FH; van Marion R; Beaufort CM; Helmijr JC; Dubbink HJ; Dinjens WNM; Ewing-Graham PC; Smolders R; van Doorn HC; Boere IA; Berns EMJJ; Helleman J; Jansen MPHM
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32156073
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Na K; Sung JY; Kim HS
    Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectrum of
    Boyarskikh UA; Gulyaeva LF; Avdalyan AM; Kechin AA; Khrapov EA; Lazareva DG; Kushlinskii NE; Melkonyan A; Arakelyan A; Filipenko ML
    Front Oncol; 2020; 10():1103. PubMed ID: 32766142
    [No Abstract]   [Full Text] [Related]  

  • 26. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
    Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
    Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
    Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
    Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
    Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
    McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
    Kolasa IK; Rembiszewska A; Janiec-Jankowska A; Dansonka-Mieszkowska A; Lewandowska AM; Konopka B; Kupryjańczyk J
    Gynecol Oncol; 2006 Nov; 103(2):692-7. PubMed ID: 16793127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The G199X and V157fs mutations in the
    Su D; Nie M; Yue J
    Ann Transl Med; 2021 Apr; 9(8):710. PubMed ID: 33987408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
    Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Mutation Profiles with Postoperative Survival in Patients with Non-Small Cell Lung Cancer.
    Goto T; Kunimasa K; Hirotsu Y; Nakagomi T; Yokoyama Y; Higuchi R; Otake S; Oyama T; Amemiya K; Mochizuki H; Omata M
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal Evolution of
    Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
    Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    Rzepecka IK; Szafron LM; Stys A; Felisiak-Golabek A; Podgorska A; Timorek A; Sobiczewski P; Pienkowska-Grela B; El-Bahrawy M; Kupryjanczyk J
    Gynecol Oncol; 2017 Feb; 144(2):369-376. PubMed ID: 27939982
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
    BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can
    Kasherman L; Garg S; Tchrakian N; Clarke B; Karakasis K; Kim RH; Stockley TL; Dhani N; Oza AM; Lheureux S
    Gynecol Oncol Rep; 2021 May; 36():100729. PubMed ID: 33718561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.